CD47–SIRPα-targeting drugs, such as magrolimab and various SIRPα antibodies, have entered multiple clinical trials in oncology; however, known safety risks such as anemia and thrombocytopenia have been identified. This evidence concerns the gene SIRPA and anemia (phenotype).